Seminars in Pediatric Neurology
Volume 15, Issue 3 , Pages 140-149 , September 2008

Mitochondrial Fatty-Acid Oxidation Disorders

  • Michelle Kompare, MD
    • ,
  • William B. Rizzo, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to William B. Rizzo, MD, Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE 68198

References 

  1. Roe CR, Ding J. Mitochondrial fatty acid disorders, in. In:  Scriver CR,  Beaudet AL,  Sly WS editor. The Metabolic & Molecular Bases of Inherited Disease. (ed 8). New York, NY: McGraw-Hill; 2001;p. 2297–2326
  2. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003;49:1797–1817
  3. Wanders RJA, Barth PG, Heymans HAS. Single peroxisomal enzyme deficiencies, in. In:  Scriver CR,  Beaudet AL,  Sly WS editor. The Metabolic & Molecular Bases of Inherited Disease. (ed 8). New York, NY: McGraw-Hill; 2001;p. 3219–3256
  4. Ghisla S. β-oxidation of fatty acids (A century of discovery). Eur J Biochem. 2004;271:459–461
  5. Foster DW. The role of the carnitine system in human metabolism. Ann N Y Acad Sci. 2004;1033:1–16
  6. Stanley CA. Carnitine deficiency disorders in children. Ann N Y Acad Sci. 2004;1033:42–51
  7. He M, Rutledge SL, Kelly DR, et al. A new genetic disorder in mitochondrial fatty acid β-oxidation: ACAD9 deficiency. Am J Hum Genet. 2007;81:87–103
  8. Angdisen J, Moore VD, Cline JM, et al. Mitochondrial trifunctional protein defects: Molecular basis and novel therapeutic approaches. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:27–40
  9. Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: Impact of expanded newborn screening on their diagnosis and management. Pediatr Res. 2005;57:78R–86R
  10. Longo N, di San Filippo CA, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet Part C. 2006;142C:77–85
  11. Ogier de Baulney H, Slama A, Touati G, et al. Neonatal hyperammonemia caused by a defect of carnitine-acylcarnitine translocase. J Pediatr. 1995;127:723–728
  12. Sigauke E, Rakheja D, Kitson K, et al. Carnitine palmitoyltransferase II deficiency: A clinical, biochemical, and molecular review. Lab Invest. 2003;83:1543–1554
  13. Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency (Clinical and molecular genetic features and diagnostic aspects). Arch Neurol. 2005;62:37–41
  14. Bonnefont JP, Djouadi F, Prip-Buus C, et al. Carnitine palmitoyltransferases 1 and 2: Biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25:495–520
  15. Djouadi F, Aubey F, Schlemmer D, et al. Peroxisome proliferators activated receptor δ (PPAR δ) agonist but not PPARα corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab. 2005;90:1791–1797
  16. Voermans NC, van Engelen BG, Kluijtmans LA, et al. Rhabdomyolysis caused by an inherited metabolic disease: Very long-chain acyl-CoA dehydrogenase deficiency. Am J Med. 2006;119:176–183
  17. Doi T, Abo W, Tateno M, et al. Milder childhood form of very long-chain acyl-CoA dehydrogenase deficiency in a 6-year old Japanese boy. Eur J Pediatr. 2000;159:9908–9911
  18. Hoffman JD, Steiner RD, Paradise L, et al. Rhabdomyolysis in the military: Recognizing late-onset very long-chain acyl CoA dehydrogenase deficiency. Mil Med. 2006;171:657–658
  19. Liebig M, Schymik I, Meuller M, et al. Neonatal screening for very long-chain acyl-CoA dehydrogenase deficiency: Enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics. 2006;118:1065–1069
  20. Primassin S, Ter Veld F, Mayatepek E, et al. Carnitine supplementation induces acylcarnitine production in tissues of very long-chain acyl-CoA dehydrogenase-deficient mice, without replenishing low free carnitine. Pediatr Res. 2008;63:632–637
  21. Grosse SD, Khoury MJ, Greene CL, et al. The epidemiology of medium-chain acyl-CoA dehydrogenase deficiency: An update. Genet Med. 2006;8:205–212
  22. Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: A cohort study. Lancet. 2007;369:37–42
  23. Derks TG, Reijngoud DJ, Waterham HR, et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: Clinical presentation and outcome. J Pediatr. 2006;148:665–670
  24. Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem. 1997;43:2106–2113
  25. Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child. 1999;80:459–462
  26. van Maldegem BT, Duran M, Wanders RJ, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA. 2006;296:943–952
  27. Bok LA, Vreken P, Wijburg FA, et al. Short-chain acyl-CoA dehydrogenase deficiency: Studies in a large family adding to the complexity of the disorder. Pediatrics. 2003;112:1152–1155
  28. Bhala A, Willi SM, Rinaldo P, et al. Clinical and biochemical characterization of short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr. 1995;126:910–915
  29. Amendt BA, Greene C, Sweetman L, et al. Short-chain acyl-coenzyme A dehydrogenase deficiency (Clinical and biochemical studies in two patients). J Clin Invest. 1987;79:1303–1309
  30. Dawson DB, Waber L, Hale DE, et al. Transient organic aciduria and persistent lacticacidemia in a patient with short-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr. 1995;126:69–71
  31. Yang S-Y, He X-Y, Schulz H. 3-Hydroxyacyl-coA dehydrogenase and short chain 3-hydroxyacyl-coA dehydrogenase in human health and disease. FEBS J. 2005;272:4874–4883
  32. Clayton PT, Eaton S, Aynsley-Green A, et al. Hyperinsulinism in short-chain L-3-hydroxyacyl-CoA dehydrogenase deficiency reveals the importance of β-oxidation in insulin secretion. J Clin Invest. 2001;108:457–465
  33. Bennett MJ, Weinberger MJ, Kobori JA, et al. Mitochondrial short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: A new defect of fatty acid oxidation. Pediatr Res. 1996;39:185–188
  34. De León DD, Stanley CA. Mechanisms of disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2007;3:57–68
  35. Tyni T, Pihko H. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Acta Paediatr. 1999;88:237–245
  36. den Boer ME, Wanders RJ, Morris AA, et al. Heymans SA, Wijburg FA (Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: Clinical presentation and follow-up of 50 patients). Pediatrics. 2002;109:99–104
  37. Rakheja D, Bennett MJ, Rogers BB. Long-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: A molecular and biochemical review. Lab Invest. 2002;82:815–824
  38. Tyni T, Paetau A, Strauss AW, et al. Mitochondrial fatty acid β-oxidation in the human eye and brain: Implications for the retinopathy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Pediatr Res. 2004;56:744–750
  39. Oey NA, den Boer ME, Wijburg FA, et al. Long-chain fatty acid oxidation during early human development. Pediatr Res. 2005;57:755–759
  40. Tyni T, Palotie A, Viinikka L, et al. Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency with the G1528C mutation: Clinical presentation of thirteen patients. J Pediatr. 1997;130:67–76
  41. Lund AM, Leonard JV. Feeding difficulties in long-chain 3-hydroxyacyl-Coa dehydrogenase deficiency. Arch Dis Child. 2001;85:487–488
  42. Tein I, Vajsar J, VacMillan L, et al. Long-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency neuropathy: Response t cod liver oil. Neurology. 1999;52:640–643
  43. Jackson S, Kler RS, Bartlett K, et al. Combined enzyme defect of mitochondrial fatty acid oxidation. J Clin Invest. 1992;90:1219–1225
  44. Wanders RJ, IJlst L, Poggi F, et al. Human trifunctional protein deficiency: A new disorder of mitochondrial fatty acid beta-oxidation. Biochem Biophys Res Commun. 1992;188:1139–1145
  45. Spiekerkoetter U, Bennett MJ, Ben-Zeev B, et al. Peripheral neuropathy, episodic myoglobinuria, and respiratory failure in deficiency of the mitochondrial trifunctional protein. Muscle Nerve. 2004;29:66–72
  46. Den Boer ME, Dionisis-Vici C, Chakrapani A, et al. Mitochondrial trifunctional protein deficiency: A severe fatty acid oxidation disorder with cardiac and neurologic involvement. J Pediatr. 2003;142:684–689
  47. Yamazaki H, Torigoe K, Numata O, et al. Mitochondrial trifunctional protein deficiency in a lethal neonate. Pediatr Int. 2004;46:178–180
  48. Schwab KO, Ensenauer R, Matern D, et al. Complete deficiency of mitochondrial trifunctional protein due to a novel mutation within the β-subunit of the mitochondrial trifunctional protein gene leads to failure of long-chain fatty acid β-oxidation with fatal outcome. Eur J Pediatr. 2003;162:90–95
  49. Das AM, Illsinger S, Lücke T, et al. Isolated mitochondrial long-chain ketoacyl-CoA thiolase deficiency resulting from mutations in the HADHB gene. Clin Chem. 2006;52:530–534
  50. Yu W, Chu X, Chen G, et al. Studies of human mitochondrial 2,4-dienoyl-CoA reductase. Arch Biochem Biophys. 2005;434:195–200
  51. Roe CR, Millington DS, Norwood DL, et al. 2,4-Dienoyl-coenzyme A reductase deficiency: A possible new disorder of fatty acid oxidation. J Clin Invest. 1990;85:1703–1707

PII: S1071-9091(08)00051-X

doi: 10.1016/j.spen.2008.05.008

Seminars in Pediatric Neurology
Volume 15, Issue 3 , Pages 140-149 , September 2008

Article Tools

* Image Usage & Resolution